Csenge Advisory Group Sells 3,192 Shares of Intuitive Surgical, Inc. $ISRG

Csenge Advisory Group lowered its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 57.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,336 shares of the medical equipment provider’s stock after selling 3,192 shares during the period. Csenge Advisory Group’s holdings in Intuitive Surgical were worth $1,045,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Ritholtz Wealth Management grew its stake in Intuitive Surgical by 0.8% in the third quarter. Ritholtz Wealth Management now owns 5,676 shares of the medical equipment provider’s stock worth $2,539,000 after purchasing an additional 43 shares during the period. Davis Rea LTD. purchased a new stake in shares of Intuitive Surgical in the 3rd quarter worth about $6,920,000. Dillon & Associates Inc. grew its position in shares of Intuitive Surgical by 5.3% in the 3rd quarter. Dillon & Associates Inc. now owns 28,474 shares of the medical equipment provider’s stock worth $12,728,000 after buying an additional 1,436 shares during the period. Gilliland Jeter Wealth Management LLC increased its stake in shares of Intuitive Surgical by 3.5% in the 3rd quarter. Gilliland Jeter Wealth Management LLC now owns 5,082 shares of the medical equipment provider’s stock worth $2,273,000 after acquiring an additional 173 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC lifted its position in Intuitive Surgical by 177.2% during the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 12,600 shares of the medical equipment provider’s stock valued at $5,635,000 after acquiring an additional 8,055 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Phase‑3 update on IS‑001 imaging drug — Intuitive advanced its Phase‑3 study aimed at reducing ureter injuries in robotic colorectal surgery, a safety-focused adjoint that could expand the company’s addressable offering and reinforce surgical‑safety differentiation. Intuitive Surgical Advances Phase 3 Imaging Drug
• Positive Sentiment: daVinci systems demand highlighted — Company commentary and industry coverage say system performance “exceeded expectations” and Intuitive is pushing for more placements, supporting procedure growth and recurring consumable revenue. Intuitive says daVinci systems ‘exceeded expectations,’ it wants more
• Positive Sentiment: Analyst support remains — At least some brokers (e.g., Bernstein) have reiterated buy ratings, signaling continued sell‑side conviction in ISRG’s long‑term growth profile despite near‑term noise. Bernstein Sticks to Their Buy Rating for Intuitive Surgical (ISRG)
• Positive Sentiment: Investor take: “buying the dip” narratives are emerging — Several bullish commentaries argue the pullback is an entry point given Intuitive’s wide moat, recurring consumables and procedure tailwinds. Intuitive Surgical: Buying The Dip On This Wide-Moat Compounder
• Neutral Sentiment: Analysts preparing for Q4 — Preview pieces outline the metrics (procedures, system placements, ASPs, margin drivers) that will matter when full Q4 results and guidance details arrive; these previews can amplify volatility around the print. Intuitive Surgical (ISRG) Q4 Earnings on the Horizon
• Neutral Sentiment: Brokerage commentary roundup — Coverage pieces remind investors that analyst ratings and model changes often move shares; they’re useful context but not a definitive signal by themselves. Brokers Suggest Investing in Intuitive Surgical (ISRG)
• Negative Sentiment: Preliminary Q4 revenue reaction — Although Intuitive reported strong preliminary Q4 and full‑year revenue growth, shares dipped as investors parsed procedure trends, margin dynamics and what management said about demand cadence. That disconnect between a beat and stock action is a key reason for the pullback. Intuitive Surgical Stock Dips on Q4 Preliminary Revenue Results
• Negative Sentiment: Softer 2026 outlook flagged — Company commentary and reporting point to a softer 2026 outlook that trimmed forward expectations, which is the primary negative driver behind today’s weakness. Intuitive Surgical Sets Softer 2026 Outlook
• Negative Sentiment: Market reaction analysis — Coverage asking “why did shares dive?” notes investors punished the stock for guidance/trajectory concerns despite the beat, illustrating that forward commentary and margin clarity matter more than one‑time beats. Intuitive Surgical Crushed Fourth-Quarter Forecasts. So Why Did Shares Dive?

Intuitive Surgical Price Performance

ISRG stock opened at $535.00 on Monday. The stock has a market capitalization of $191.79 billion, a P/E ratio of 70.77, a P/E/G ratio of 4.35 and a beta of 1.67. Intuitive Surgical, Inc. has a 1-year low of $425.00 and a 1-year high of $616.00. The business has a fifty day moving average price of $566.32 and a 200-day moving average price of $511.86.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Tuesday, October 21st. The medical equipment provider reported $2.40 EPS for the quarter, topping the consensus estimate of $1.99 by $0.41. The company had revenue of $2.51 billion during the quarter, compared to the consensus estimate of $2.41 billion. Intuitive Surgical had a return on equity of 15.08% and a net margin of 28.58%.Intuitive Surgical’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same period last year, the company earned $1.84 EPS. As a group, analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ISRG. Argus raised their target price on shares of Intuitive Surgical from $600.00 to $630.00 in a research note on Monday, October 27th. BTIG Research reaffirmed a “buy” rating and set a $616.00 price objective (up previously from $589.00) on shares of Intuitive Surgical in a research report on Wednesday, January 7th. The Goldman Sachs Group reiterated a “buy” rating and set a $714.00 price objective on shares of Intuitive Surgical in a research note on Friday, January 9th. Barclays reissued an “overweight” rating and issued a $686.00 target price (up from $635.00) on shares of Intuitive Surgical in a research note on Wednesday, January 7th. Finally, Hsbc Global Res raised Intuitive Surgical to a “strong-buy” rating in a research report on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $622.17.

Insider Buying and Selling

In other Intuitive Surgical news, SVP Mark Brosius sold 464 shares of the business’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $548.49, for a total transaction of $254,499.36. Following the completion of the sale, the senior vice president directly owned 131 shares in the company, valued at approximately $71,852.19. The trade was a 77.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Henry L. Charlton sold 13,731 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $580.00, for a total value of $7,963,980.00. Following the completion of the transaction, the executive vice president owned 3,056 shares in the company, valued at approximately $1,772,480. This trade represents a 81.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 114,007 shares of company stock valued at $63,533,844 in the last ninety days. Corporate insiders own 0.70% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.